Patent · US Active

Fusion protein for use in the treatment of HvG disease

US11160831B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignees

MEDIZINISCHE HOCHSCHULE HANNOVER · DE
TECHNISCHE UNIVERSITAT BRAUNSCHWEIG · DE

Inventors

Elmar Jäckel · Hannover, DE
Fatih Noyan · Hannover, DE
Michael Hust · Hannover, DE

Key dates

Filing date	Jun 22, 2017
Grant date	Nov 2, 2021
Priority date	—
Expiry date	Jul 10, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.